In this issue:
Etanercept withdrawal for nrAxSpA patients
Risk factors for musculoskeletal surgery in PsA patients
Inflammation progress in nrAxSpA patients
Predicting low function impairment in axSpA
Targeted therapy impacts on CV risk
Prevalence of undiagnosed axSpA
Comparison of MRI and conventional radiography for the SI joint
Sleep disturbance prevalence in PsA
Validity of patient-reported flares
AE occurrence after etanercept treatment
Please login below to download this issue (PDF)